ArticleACS pharmacology & translational science2026
Studying the Molecule, Assuming the Experience: The Pharmacology-Experience Asymmetry Framework for Psychedelic Research.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contemporary models of psychedelic action hold that clinical outcomes arise from an interaction between a pharmacologically induced brain state and the lived experience that unfolds within it. Research effort is distributed very unevenly across those two domains: pharmacological variables receive dose-finding trials, power calculations, and effect-size estimates, while the variables that shape experience are frequently unreported, rarely manipulated, and almost never compared. I argue that this imbalance rests on a conceptual error about what is being administered, and propose that the object of psychedelic therapy is best understood as the pharmacologically scaffolded experience. On that basis I describe the Pharmacology-Experience Asymmetry and develop a framework (PEAF) built on six postulates: the intervention comprises two conceptually distinguishable components; therapeutic mechanisms span two partially differentiable domains; the elements that organize experience constitute a specifiable class of experiential inputs, with a taxonomy and a fixed-to-adaptive delivery axis; measurement effort is asymmetrically distributed between domains; several current conventions may represent crystallized methodological decisions rather than conclusions from comparative evidence; and investigative effort should be approximately proportional to the causal weight attributed to each domain. I distinguish experiential inputs, process, and outcomes, examine why the asymmetry has persisted for six decades, and address anticipated objections. Music serves as the illustrative case: a recent scoping review identified 19 papers from 10 studies across five decades, with one fully factorial design and one no-music arm, published in 1970. Five testable predictions are derived, including one that requires no new participants. Treating experiential inputs as tractable variables rather than uncontrolled background would allow psychedelic research to investigate them with methodological effort proportionate to the causal weight assigned to experience by its own mechanistic models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.